AnaptysBio (NASDAQ:ANAB) Posts Earnings Results, Beats Estimates By $0.58 EPS

AnaptysBio (NASDAQ:ANAB) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58, Zacks reports. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The company had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million.

AnaptysBio Price Performance

NASDAQ ANAB opened at $22.21 on Thursday. The stock has a market capitalization of $609.31 million, a PE ratio of -3.50 and a beta of -0.24. AnaptysBio has a 1-year low of $13.36 and a 1-year high of $41.31. The business has a 50 day simple moving average of $33.30 and a two-hundred day simple moving average of $29.89.

Insider Activity

In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares in the company, valued at $189,333.04. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the transaction, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Dennis Mulroy sold 12,220 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the transaction, the chief financial officer now directly owns 4,744 shares in the company, valued at approximately $189,333.04. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ANAB. Guggenheim upped their price target on shares of AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. JPMorgan Chase & Co. upped their target price on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Wedbush reissued an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a report on Wednesday. Truist Financial upped their price objective on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. Finally, UBS Group lifted their target price on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $55.45.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.